Drugs / D1/3-MAGE-3-His fusion protein
D1/3-MAGE-3-His fusion protein
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00086866 Background | May 2004 → Jan 2007 | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D1/3-MAGE-3-His fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00086866 ↗ |
| Modality | Protein / enzyme biologic | “MAGE-3 protein” NCT00086866 ↗ |
| Route | Intramuscular | “D1/3-MAGE-3-His fusion protein and SB-AS02B adjuvant intramuscularly (IM)” NCT00086866 ↗ |